Advertisement

Pediatric Drugs

, Volume 10, Issue 4, pp 217–254 | Cite as

Use of Second-Generation Antiepileptic Drugs in the Pediatric Population

  • Allison M. ChungEmail author
  • Lea S. Eiland
Review Article

Abstract

Epilepsy is common in the pediatric population. Nine second-generation antiepileptic drugs have been approved in the US for use in epilepsy over the past 15 years: felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, zonisamide, and pregabalin. Their use in pediatric patients is fairly widespread, despite most of these agents not having US FDA indications for use.

Felbamate and gabapentin were the first two second-generation antiepileptic drugs to be approved in the US. Felbamate use has been limited because of the occurrence of hepatotoxicity and aplastic anemia. Although gabapentin is a fairly well tolerated antiepileptic drug, its use has also been limited as a result of inconsistent efficacy and concern about seizure exacerbation. Lamotrigine and topiramate are broad-spectrum antiepileptic drugs with efficacy in a wide variety of seizure types. Both agents have some tolerability concerns: rash with lamotrigine and neuropsychiatric events with topiramate. There are very little data on tiagabine use in children, but this agent appears to be effective and to have a good tolerability profile. Levetiracetam is a second-generation antiepileptic agent that is available intravenously. Considering its good efficacy, fast onset of action, and low incidence of serious adverse effects, its use in the acute setting could potentially increase. Oxcarbazepine and zonisamide have been relatively well studied in pediatric seizure patients, including use as monotherapy. Both agents have demonstrated good efficacy and tolerability for patients as young as 1 month old. Vigabatrin and rufinamide are currently not available in the US, but have been shown to have some success in other countries. Pregabalin is the newest antiepileptic agent, but lacks pediatric data currently.

Keywords

Valproic Acid Gabapentin Lamotrigine Topiramate Pregabalin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

No source of funding was provided for performing this review. Drs Chung and Eiland do not have any conflicts of interest. The authors thank Wesley Lindsey, David Mann, and Bernie Olin for their patience and assistance.

References

  1. 1.
    Guerrini R. Epilepsy in children. Lancet 2006; 367: 499–524PubMedGoogle Scholar
  2. 2.
    Bebin M. Pediatric partial and generalized seizures. J Child Neurol 2002; 17: S65–9PubMedGoogle Scholar
  3. 3.
    The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993 Jan 7; 328(1): 29–33Google Scholar
  4. 4.
    Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999 Apr; 34(2-3): 91–7PubMedGoogle Scholar
  5. 5.
    Carmant L, Holmes GL, Sawyer S, et al. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994 Sep; 125(3): 481–6PubMedGoogle Scholar
  6. 6.
    Cilio MR, Kartashov AI, Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001 Nov; 47(1-2): 1–7PubMedGoogle Scholar
  7. 7.
    Espe-Lillo J, Ritter FJ. Long-term follow-up of felbamate treatment in children with Lennox-Gastaut syndrome [abstract]. Epilepsia 1992; 33Suppl. 3: 118Google Scholar
  8. 8.
    Khurana DS, Riviello J, Helmers S, et al. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996 Jun; 128(6): 829–33PubMedGoogle Scholar
  9. 9.
    Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 1999 Aug; 40(8): 1147–54PubMedGoogle Scholar
  10. 10.
    Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study. Dev Med Child Neurol 2001 Apr; 43(4): 269–73PubMedGoogle Scholar
  11. 11.
    Korn-Merker E, Borusiak P, Boenigk HE. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res 2000; 38: 27–32PubMedGoogle Scholar
  12. 12.
    McDonald DG, Najam Y, Keegan MB, et al. The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. Seizure 2005 Mar; 14(2): 112–6PubMedGoogle Scholar
  13. 13.
    Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002 Sep; 43(9): 993–1000PubMedGoogle Scholar
  14. 14.
    Khan RB, Hunt DL, Thompson SJ. Gabapentin to control seizures in children undergoing cancer treatment. J Child Neurol 2004 Feb; 19(2): 97–101PubMedGoogle Scholar
  15. 15.
    Trudeau V, Myers S, LaMoreaux L, et al. Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996 Nov; 11(6): 470–5PubMedGoogle Scholar
  16. 16.
    Mikati MA, Fayad M, Koleilat M, et al. Efficacy, tolerability, and kinetics of lamotrigine in infants. J Pediatr 2002 Jul; 141(1): 31–5PubMedGoogle Scholar
  17. 17.
    Nieto-Barrera M, Brozmanova M, Capovilla G, et al. Lamictal vs. Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001 Aug; 46(2): 145–55PubMedGoogle Scholar
  18. 18.
    Kaminow L, Schimschock JR, Hammer AE, et al. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav 2003 Dec; 4(6): 659–66PubMedGoogle Scholar
  19. 19.
    Coppola G, Auricchio G, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 2004 Sep; 45(9): 1049–53PubMedGoogle Scholar
  20. 20.
    Thome-Souza S, Freitas A, Fiore LA, et al. Lamotrigine and valproate: efficacy of co-administration in a pediatric population. Pediatr Neurol 2003 May; 28(5): 360–4PubMedGoogle Scholar
  21. 21.
    Trevanthan E, Keris SP, Hammer AE, et al. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures. Pediatrics 2006; 118(2): e371–8Google Scholar
  22. 22.
    Duchowny M, Gilman J, Messenheimer J, et al. LAMICTAL Pediatric Study Group. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol 2002 Apr; 17(4): 278–85PubMedGoogle Scholar
  23. 23.
    Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39: 1324–8PubMedGoogle Scholar
  24. 24.
    Glauser TA, Levisohn PM, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Epilepsia 2000; 41: S86–90PubMedGoogle Scholar
  25. 25.
    Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000; 41: S91–4PubMedGoogle Scholar
  26. 26.
    Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999; 52: 1882–7PubMedGoogle Scholar
  27. 27.
    Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neuorology 1999; 52: 1338–44Google Scholar
  28. 28.
    Biton V, Bourgeois B. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 2005; 62: 1705–8PubMedGoogle Scholar
  29. 29.
    Ritter F, Glauser TA, Elterman RD, et al., on behalf of the Topiramate YP Study Group. Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000; 41: S82–5PubMedGoogle Scholar
  30. 30.
    Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 2000; 9: 580–94Google Scholar
  31. 31.
    Hosain SA, Mechant S, Solomon GE, et al. Topiramate for the treatment of infantile spasms. J Child Neurol 2006; 21: 17–9PubMedGoogle Scholar
  32. 32.
    Valencia I, Fons C, Kothare S, et al. Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol 2005; 20: 667–70PubMedGoogle Scholar
  33. 33.
    Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: Double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol 2004; 19: 135–41PubMedGoogle Scholar
  34. 34.
    Gilliam FG, Reife R, Wu S-C. A dose-comparison trial of TPM as monotherapy in recently diagnosed partial epilepsy. Neurology 2003; 60: 196–201PubMedGoogle Scholar
  35. 35.
    Watemberg N, Goldberg-Stern H, Ben-Zeev B, et al. Clinical experience with open-label topiramate in infants younger than 2 years of age. J Child Neurol 2003; 18: 258–62PubMedGoogle Scholar
  36. 36.
    Grosso S, Galimberti D, Farnetani MA, et al. Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 2005; 14: 183–9PubMedGoogle Scholar
  37. 37.
    Aljouni SA, Shorman A, Daoud AS. The efficacy and side effects of topiramate on refractory epilepsy in infants and young children: a multi-center clinical trial. Seizure 2005; 14: 459–63Google Scholar
  38. 38.
    Coppola G, Caliendo G, Terracciano M, et al. Topiramate in refractory partialonset seizures in children, adolescents and young adults: a multicentric open trial. Epilepsy Res 2001; 43: 255–60PubMedGoogle Scholar
  39. 39.
    Uldall P, Buchholt JM. Clinical experience with topiramate in children with intractable epilepsy. Europ J Paediatr Neurol 1999; 3: 105–11Google Scholar
  40. 40.
    Boellner SW, McCarty J, Mercante D, et al. Pilot study of tiagabine in children with partial seizures [abstract]. Epilepsia 1996; 37: S92Google Scholar
  41. 41.
    Uldall P, Bulteau C, Pederson A, et al. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000; 42: 159–68PubMedGoogle Scholar
  42. 42.
    Boellner SW, Deaton R, Sommerville KW. Long-term treatment of partial seizures with tiagabine in children [abstact]. Epilepsia 1997; 38: S208Google Scholar
  43. 43.
    Glauser T, Pellock J, Bebin M, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43(5): 518–24PubMedGoogle Scholar
  44. 44.
    Glauser TA, Gauer LJ, Chen L, et al. Multicenter, double-blind, placebo-controlled trial of adjunctive levetiracetam (Keppra) therapy (up to 60 mg/kg/day) in pediatric patients with refractory partial epilepsy [abstract]. Epilepsia 2004; 45: 186Google Scholar
  45. 45.
    Koukkari MW, Guarino EJ. Retrospective study of the use of levetiracetam in childhood seizure disorders. J Child Neurol 2004; 19: 944–7PubMedGoogle Scholar
  46. 46.
    Grosso S, Franzoni E, Coppola G, et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 2005; 14: 248–53PubMedGoogle Scholar
  47. 47.
    Tan MJ, Appleton RE. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 2004; 13: 142–5PubMedGoogle Scholar
  48. 48.
    Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476–84PubMedGoogle Scholar
  49. 49.
    Frost MD, Gustafson MC, Ritter FJ. Use of levetiracetam (LEV) in children younger than 2 years [abstract]. Epilepsia 2002; 42: S57Google Scholar
  50. 50.
    Mandelbaum DE, Kugler SL, Wenger EC, et al. Clinical experience with levetiracetam and zonisamide in children with uncontrolled epilepsy [abstract]. Epilepsia 2001; 42Suppl. 7: 182Google Scholar
  51. 51.
    Coppola G, Mangano S, Tortorella G, et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 2004; 59: 35–42PubMedGoogle Scholar
  52. 52.
    Nakken KO, Eriksson AS, Lossius R, et al. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003; 12: 42–6PubMedGoogle Scholar
  53. 53.
    Lagae L, Buyse G, Deconinck A, et al. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Ped Neurol 2003; 7: 123–8Google Scholar
  54. 54.
    Wheless J, Ng Y. Levetiracetam in refractory pediatric epilepsy. J Child Neuro 2002; 17: 413–5Google Scholar
  55. 55.
    Pina-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005; 65: 1370–5PubMedGoogle Scholar
  56. 56.
    Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54: 2237–44PubMedGoogle Scholar
  57. 57.
    Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205–13PubMedGoogle Scholar
  58. 58.
    Gaily E, Granstrom M-J, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12: 496–8PubMedGoogle Scholar
  59. 59.
    Tzitiridou M, Panou T, Ramantani G, et al. Oxcarbazepine monotherapy in benign childhood epilepsy with centrotemperal spikes: a clinical and cognitive evaluation. Epilepsy Behav 2005; 7: 458–67PubMedGoogle Scholar
  60. 60.
    Serdaroglu G, Kurul S, Tutuncuoglu S, et al. Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003; 28: 37–41PubMedGoogle Scholar
  61. 61.
    Northam RS, Hernandez AW, Litzinger MJ, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 2005; 33: 337–44PubMedGoogle Scholar
  62. 62.
    Kothare SV, Mostofi N, Khurana D, et al. Oxcarbazepine therapy in very young children: a single-center clinical experience. Pediatr Neurol 2006; 35: 173–6PubMedGoogle Scholar
  63. 63.
    Rufo-Campus M, Casas-Fernández C, Martinez-Bermejo A. Long-term use ofoxcarbazepine oral suspension in childhood epilepsy: open-label study. J Child Neurol 2006; 21: 480–5Google Scholar
  64. 64.
    Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005 Mar; 20(3): 212–9PubMedGoogle Scholar
  65. 65.
    Iinuma K, Haginoya K. Clinical efficacy of zonisamide in childhood epilepsy after long-term treatment: a postmarketing, multi-institutional survey. Seizure 2004; 13: S34–9PubMedGoogle Scholar
  66. 66.
    Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2005; 13: S26–32Google Scholar
  67. 67.
    Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005 Jan; 46(1): 31–41Google Scholar
  68. 68.
    Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001 Nov 27; 57(10): 1774–9PubMedGoogle Scholar
  69. 69.
    Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004 Jan 27; 62(2): 296–8PubMedGoogle Scholar
  70. 70.
    Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006 May; 34(5): 351–4PubMedGoogle Scholar
  71. 71.
    Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005 Feb; 32(2): 77–80PubMedGoogle Scholar
  72. 72.
    Santos CC, Brotherton T. Use of zonisamide in pediatric patients. Pediatr Neurol 2005; 33: 12–4PubMedGoogle Scholar
  73. 73.
    Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004 Dec; 6(4): 267–70PubMedGoogle Scholar
  74. 74.
    Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005 Mar-Apr; 64(1-2): 31–4PubMedGoogle Scholar
  75. 75.
    Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; (3): CD003277Google Scholar
  76. 76.
    Pellock JM. Felbamate. Epilepsia 1999; 40Suppl. 5: S57–62PubMedGoogle Scholar
  77. 77.
    Kelley MT, Walson PD, Cox S, et al. Population pharmacokinetics of felbamate in children. Ther Drug Monit 1997; 19(1): 29–36PubMedGoogle Scholar
  78. 78.
    Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed? Clin pharmacokinet 2006; 45(11): 1061–75PubMedGoogle Scholar
  79. 79.
    Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995 Mar; 10(2): 134–6PubMedGoogle Scholar
  80. 80.
    Devinsky O, Kothari M, Rubin R, et al. Felbamate for absence seizures [abstract]. Epilepsia 1992; 33Suppl. 3: 84Google Scholar
  81. 81.
    Sachdeo RC, Murphy JV, Kamin TM. Felbamate in juvenile myoclonic epilepsy [abstract]. Epilepsia 1992; 33Suppl. 3: 118Google Scholar
  82. 82.
    Kerrick JM, Kelley BJ, Maister BH, et al. Involuntary movement disorders associated with felbamate. Neurology 1995 Jan; 45(1): 185–7PubMedGoogle Scholar
  83. 83.
    Taketomo CK, Hodding JH, Kraus DM. Pediatric dosing handbook. 12th ed. Hudson (NY): Lexi-Comp, 2005–2006Google Scholar
  84. 84.
    Haig GM, Bockbrader HN, Wesche DL, et al. Single-dose gabapentin pharmacokinetics and safety in healthy infants and children. J Clin Pharmacol 2001 May; 41(5): 507–14PubMedGoogle Scholar
  85. 85.
    Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6(1): 108–13PubMedGoogle Scholar
  86. 86.
    Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73(2): 137–50PubMedGoogle Scholar
  87. 87.
    Tallian KB, Nahata MC, Lo W, et al. Pharmacokinetics of gabapentin in paediatric patients with uncontrolled seizures. J Clin Pharm Ther 2004 Dec; 29(6): 511–5PubMedGoogle Scholar
  88. 88.
    Ouellet D, Bockbrader HN, Wesche DL, et al. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res 2001 Dec; 47(3): 229–41PubMedGoogle Scholar
  89. 89.
    Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996 Mar; 46(3): 852–3PubMedGoogle Scholar
  90. 90.
    Tallian KB, Nahata MC, Lo W, et al. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996 May; 37(5): 501–2PubMedGoogle Scholar
  91. 91.
    Wolf SM, Shinnar S, Kang H, et al. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995 Dec; 36(12): 1203–5PubMedGoogle Scholar
  92. 92.
    Culy CR, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Paediatr Drugs 2000; 2(4): 299–330PubMedGoogle Scholar
  93. 93.
    Chen C, Casale EJ, Duncan B, et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy 1999; 19(4): 437–41PubMedGoogle Scholar
  94. 94.
    Vauzelle-Kervroedan F, Rey E, Cieuta C, et al. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol 1996 Apr; 41(4): 325–30PubMedGoogle Scholar
  95. 95.
    Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991; 32Suppl. 2: S9–12PubMedGoogle Scholar
  96. 96.
    Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patient with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457–65PubMedGoogle Scholar
  97. 97.
    Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47(1-2): 151–4PubMedGoogle Scholar
  98. 98.
    Messenheimer J. Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol 2002 Feb; 17Suppl. 2: 2S34–42PubMedGoogle Scholar
  99. 99.
    Lamictal (lamotrigine) [package insert]. Research Triangle Park (NC): Glaxo-SmithKline, 2006Google Scholar
  100. 100.
    Das KB, Harris C, Smyth DP, et al. Unusual side effects of lamotrigine therapy. J Child Neurol 2003 Jul; 18(7): 479–80PubMedGoogle Scholar
  101. 101.
    Chattergoon DS, McGuigan MA, Koren G, et al. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Neurology 1997; 19: 1442–4Google Scholar
  102. 102.
    Nahata MC, Morosco RS, Hippie TF. Stability of lamotrigine in two extemporaneously prepared oral suspensions at 4°C and 25°C. Am J Health Syst Pharm 1999; 56(3): 241–2Google Scholar
  103. 103.
    White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997; 28: 167–79PubMedGoogle Scholar
  104. 104.
    Taverna S, Sancini G, Mantegazza M, et al. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 1999; 288: 960–8PubMedGoogle Scholar
  105. 105.
    DeLorenzo RJ, Sombati S, Coulter DA. Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 2000; 41: S40–4PubMedGoogle Scholar
  106. 106.
    Gibbs 3rd JW, Sombati S, DeLorenzo RJ, et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000; 41: S10–6PubMedGoogle Scholar
  107. 107.
    Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000; 41: S35–9PubMedGoogle Scholar
  108. 108.
    Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999; 20: 339–44PubMedGoogle Scholar
  109. 109.
    Mikaeloff Y, Rey E, Soufflet C, et al. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 2004; 45: 1448–52PubMedGoogle Scholar
  110. 110.
    Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36: 884–91PubMedGoogle Scholar
  111. 111.
    Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35: 241–56PubMedGoogle Scholar
  112. 112.
    Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998; 34: 335–46PubMedGoogle Scholar
  113. 113.
    Ferrari AR, Guerrini R, Giuliana G, et al. Influence of dosage, age and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003; 25: 700–8PubMedGoogle Scholar
  114. 114.
    Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy. Clin Pharmacokinet 2005; 44: 407–16PubMedGoogle Scholar
  115. 115.
    Peeters K, Adriaenssen I, Wapenaar R, et al. A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand 2003; 108: 9–15PubMedGoogle Scholar
  116. 116.
    Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38(8): 859–80PubMedGoogle Scholar
  117. 117.
    Topamax (topiramate) [package insert]. Titusville (NJ): Ortho-McNeil Neurologies Inc., 2005Google Scholar
  118. 118.
    Glauser TA. Topiramate use in pediatric patients. Can J Neurol Sci 1998; 25: S8–S12PubMedGoogle Scholar
  119. 119.
    Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997; 38: S28–30PubMedGoogle Scholar
  120. 120.
    Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165–75PubMedGoogle Scholar
  121. 121.
    Kahriman M, Minecan D, Kutluay E, et al. Efficacy of topiramte in children with refractory status epilepticus. Epilepsia 2003; 44: 1353–6PubMedGoogle Scholar
  122. 122.
    Gerber PE, Hamiwka L, Connolly MB, et al. Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurol 2000; 22: 200–3PubMedGoogle Scholar
  123. 123.
    Moreland EC, Griesemer DA, Holden KR. Topiramate for intractable childhood epilepsy. Seizure 1999; 8: 38–40PubMedGoogle Scholar
  124. 124.
    French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. I: treatment of new onset epilepsy. Report of the therapeutic and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1252–60PubMedGoogle Scholar
  125. 125.
    French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs. II: treatment of refractory epilepsy. Report of the therapeutic and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261–73PubMedGoogle Scholar
  126. 126.
    Ormrod D, McClellan K. Topiramate: a review of its use in childhood epilepsy. Paediatr Drugs 2001; 3: 293–319PubMedGoogle Scholar
  127. 127.
    Filho G, Pascalicchio T, Lin K, et al. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 2006; 8: 606–9Google Scholar
  128. 128.
    Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999; 52: 1330–7PubMedGoogle Scholar
  129. 129.
    Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001; 42: 1134–40PubMedGoogle Scholar
  130. 130.
    Reith D, Burke C, Appleton DB, et al. Tolerability of topiramate in children and adolescents. J Paediatr Child Health 2003; 39: 416–9PubMedGoogle Scholar
  131. 131.
    Jones MW. Topiramate: safety and tolerability. Can J Neurol Sci 1998; 25: S13–5PubMedGoogle Scholar
  132. 132.
    Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000; 15: S22–6PubMedGoogle Scholar
  133. 133.
    Gross-Tsur V, Shalev R. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology 2004; 62: 299–300PubMedGoogle Scholar
  134. 134.
    Lee HW, Jung DK, Suh CK, et al. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 2006; 8: 736–41PubMedGoogle Scholar
  135. 135.
    Mohamed K, Appleton R, Rosenbloom L. Efficacy and tolerability of topiramate in childhool and adolescent epilepsy: a clinical experience. Seizure 2000; 9: 137–41PubMedGoogle Scholar
  136. 136.
    Ko CH, Kong CK. Topiramate-induced metabolic acidosis: report of two cases. Dev Med Child Neurol 2001; 43: 701–4PubMedGoogle Scholar
  137. 137.
    Groeper K, McCann ME. Topiramate and metabolic acidosis: a case series and review of the literature. Pediatr Anesth 2005; 15: 167–70Google Scholar
  138. 138.
    Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002; 43: 744–7PubMedGoogle Scholar
  139. 139.
    Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001; 42: 387–92PubMedGoogle Scholar
  140. 140.
    Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-l-yl]nipecotic acid binds with high affinity to the brain gam-ma-aminobutyric acid uptake carrier. J Neurochem 1990; 54: 639–47PubMedGoogle Scholar
  141. 141.
    Luer MS and Rhoney DH. Tiagabine: a novel antiepileptic drug. Ann Pharma-cother 1998; 32: 1173–80Google Scholar
  142. 142.
    Schachter SC. Tiagabine. Epilepsia 1999; 40: S17–22PubMedGoogle Scholar
  143. 143.
    Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-upatake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995; 36: 605–11PubMedGoogle Scholar
  144. 144.
    Kalviainen R. Long-term safety of tiagabine. Epilepsia 2001; 42: S46–8Google Scholar
  145. 145.
    Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in children with complex partial seizures. Neurology 1997; 48: 1032–7PubMedGoogle Scholar
  146. 146.
    Al-jayyousi M, Helmers SL. Tiagabine in the treatment of infantile spasms [abstract]. Epilepsia 1998; 39: 166Google Scholar
  147. 147.
    Holden KR, Titus O. The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study. Pediatr Neurol 1999; 21: 728–30PubMedGoogle Scholar
  148. 148.
    Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002; (3): CD001908Google Scholar
  149. 149.
    Koepp MJ, Edwards M, Collins J, et al. Status epilepticus and tiagabine therapy revisited. Epilpesia 2005; 46: 1625–32Google Scholar
  150. 150.
    Piccinelli P, Borgatti R, Perucca E, et al. Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria. Epilepsia 2000; 41: 1484–8Google Scholar
  151. 151.
    Mangano S, Cusumano L, Fontana A. Non-conculsive status epilepticus associated with tiagabine in a pediatric patient. Brain Dev 2003; 25: 518–21PubMedGoogle Scholar
  152. 152.
    Skardoutsou A, Konstantinos AV, Bagiakou EA. Non-convulsive status epilepticus associated with tiagabine therapy in children. Seizure 2003; 12: 599–601PubMedGoogle Scholar
  153. 153.
    Balslev T, Uldall P, Buchholt J. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients. Eur J Paediatric Neurol 2000; 4: 169–70Google Scholar
  154. 154.
    Nahata MC, Morosco RS. Stability of tiagabine in two oral liquid vehicles. Am J Health-Syst Pharm 2003; 60: 75–7PubMedGoogle Scholar
  155. 155.
    Vigevano F. Levetiracetam in pediatrics. J child Neurol 2005; 20: 87–93PubMedGoogle Scholar
  156. 156.
    Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43(1): 9–18PubMedGoogle Scholar
  157. 157.
    Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001; 21(11): 1375–88PubMedGoogle Scholar
  158. 158.
    Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS 2004; 101: 9861–6PubMedGoogle Scholar
  159. 159.
    Pellock J, Glauser T, Bebin M, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574–9PubMedGoogle Scholar
  160. 160.
    Sharief MK, Singh P, Sander JWAS, et al. Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy. J Epilepsy 1996; 9: 106–12Google Scholar
  161. 161.
    Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Research 2002; 48: 217–9PubMedGoogle Scholar
  162. 162.
    Keppra (levetiracetam) [package insert]. Smyrna (GA): UCB Pharma Inc., 2006Google Scholar
  163. 163.
    Abou-Khalil A. Benefit-risk assessment of levetiracetam in the treatment of partial seizures. Drug Safety 2005; 28: 871–90PubMedGoogle Scholar
  164. 164.
    Kossoff EH, Bergey GK, Freeman JM, et al. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611–3PubMedGoogle Scholar
  165. 165.
    Miller GS. Pyridoxine ameliorates adverse behavioral effects of levetiracetam in children [abstract]. Epilepsia 2002; 43Suppl. 7: 62Google Scholar
  166. 166.
    Bang LM, Goa KL. Oxcarbazepine: a review of its use in children with epilepsy. Pediatr Drugs 2003; 5(8): 557–73Google Scholar
  167. 167.
    Phelps SJ, Wheless JW. Oxcarbazepine: a brief review. J Pediatr Pharmacol Therapeut 2005; 10: 248–53Google Scholar
  168. 168.
    Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094–120PubMedGoogle Scholar
  169. 169.
    Rey E, Bulteau C, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol 2004; 44: 1290–300PubMedGoogle Scholar
  170. 170.
    Sallas WM, Milosvljev S, D’Souza J, et al. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003; 74: 138–49PubMedGoogle Scholar
  171. 171.
    Hershkowith N. Clinical pharmacology and biopharmaceutics BPCA summary: clinical review [NDA 21-014/SE5-013 and 21-285/SE5-008]. Rockville (MD): US FDA, 2005 Jun 14Google Scholar
  172. 172.
    Bourgeois FD, D’Souza J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behavior 2005 Nov; 7(3): 375–82PubMedGoogle Scholar
  173. 173.
    Donati F, Gobbi G, Campistol J, et al. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 2006; 67: 679–82PubMedGoogle Scholar
  174. 174.
    Gelisse P, Genton P, Kuate C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282–6PubMedGoogle Scholar
  175. 175.
    Chapman K, Holland K, Erenberg G. Seizure exacerbation associated with oxcarbazepine in idiopathic focal epilepsy of childhood. Neruology 2003; 61: 1012–3Google Scholar
  176. 176.
    Grosso S, Balestri M, Di Barola RM, et al. Oxcarbazepine and atypical evolution of benign idiopathic focal epilepsy of childhood. Eu J Neuro 2006 Oct; 13(10): 1142–5Google Scholar
  177. 177.
    Kurul S, Dirik E, Iscan A. Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy. J Child Neurol 2003; 18: 552–4PubMedGoogle Scholar
  178. 178.
    Vainionpaa LK, Mikkonen K, Rattya J, et al. Thryoid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45: 197–203PubMedGoogle Scholar
  179. 179.
    Franzoni E, Marchiani V, Cecconi I, et al. Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children. Eur J Neuro 2006; 13: 1389–91Google Scholar
  180. 180.
    Rattya J, Vainionpaa L, Knip M, et al. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 588–93PubMedGoogle Scholar
  181. 181.
    Trileptal (oxcarbazepine) [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2006Google Scholar
  182. 182.
    Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005; 19(4): 347–67PubMedGoogle Scholar
  183. 183.
    Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neuro 2002; 17: 87–96Google Scholar
  184. 184.
    Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998 Feb; 38(2): 166–71PubMedGoogle Scholar
  185. 185.
    Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure 2004; 135: S17–23Google Scholar
  186. 186.
    Yagi K. Overview of Japanese experience: controlled and uncontrolled trials. Seizure 2004; 13S: S11–5Google Scholar
  187. 187.
    Suzuki Y. Zonisamide in West syndrome. Brain Dev 2001; 23: 658–61PubMedGoogle Scholar
  188. 188.
    Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004; 4: 935–43PubMedGoogle Scholar
  189. 189.
    Kimura S. Zonisamide-induced behavior disorder in two children. Epilepsia 1994 Mar-Apr; 35(2): 403–5PubMedGoogle Scholar
  190. 190.
    Miyamoto T, Kohsaka M, Koyama T. Psychotic episodes during zonisamide treatment. Seizure 2000 Jan; 9(1): 65–70PubMedGoogle Scholar
  191. 191.
    Akman CI, Goodkin HP, Rogers DP, et al. Visual hallucinations associated with zonisamide. Pharmacotherapy 2003 Jan; 23(1): 93–6PubMedGoogle Scholar
  192. 192.
    Knudsen JF, Thambi LR, Kapcala LP, et al. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 2003 Mar; 28(3): 184–9PubMedGoogle Scholar
  193. 193.
    Gidal BE, Privitera MD, Sheth RD, et al. Vigabatrin: a novel therapy for seizure disorders. Ann Pharmacother 1999; 33: 1277–86PubMedGoogle Scholar
  194. 194.
    Gobbi G, Pini A, Bertani G, et al. Prospective study of first-line vigabatrin mono-therapy in childhood partial epilepsies. Epilepsy Res 1999; 35: 29–37PubMedGoogle Scholar
  195. 195.
    Prasad AN, Penney S, Buckley DJ. The role of vigabatrin in childhood seizure disorders results from a clinical audit. Epilepsia 2001; 42: 54–61PubMedGoogle Scholar
  196. 196.
    Hancock E, Osborne J. Treatment of infantile spasms. Cochrane Database Syst Rev 2002; (2): CD001770Google Scholar
  197. 197.
    Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57: 1416–21PubMedGoogle Scholar
  198. 198.
    Nabbout R, Melki I, Gerbaka B, et al. Infantile spasms in down syndrome: good response to a short course of vigabatrin. Epilepsia 2001; 42(12): 1580–3PubMedGoogle Scholar
  199. 199.
    Appleton RE, Peters ACB, Mumford JP, et al. Randomized, placebo-controlled study of vigabatrin as frist-line treatment of infantile spasms. Epilepsia 1999; 40(11): 1627–33PubMedGoogle Scholar
  200. 200.
    Vigevano F, Cilio MR. Vigabatrin vs ACTH as first-line treatment for infantile spasms: a randomized prospective study. Epilepsia 1997; 38: 1270–4PubMedGoogle Scholar
  201. 201.
    Mackay MT. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62(10): 1668–81PubMedGoogle Scholar
  202. 202.
    Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing vigabatrin with prednisolone or tetracosac-tide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364: 1773–8PubMedGoogle Scholar
  203. 203.
    Askalan R, Mackay M, Brian J, et al. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. J Child Neurol 2003; 18: 165–70PubMedGoogle Scholar
  204. 204.
    Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389–95PubMedGoogle Scholar
  205. 205.
    Vigabatrin Paediatric Advisory Group. Guideline for prescribing vigabatrin in children has been revised. BMJ 2000; 320: 1404–5Google Scholar
  206. 206.
    Appleton RE. Guideline may help in prescribing vigabatrin [letter]. BMJ 1998; 317: 1322PubMedGoogle Scholar
  207. 207.
    Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol 2004; 19: 401–4PubMedGoogle Scholar
  208. 208.
    Lux Al, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomized trial. Lancet Neurol 2005; 4: 712–7PubMedGoogle Scholar
  209. 209.
    Coseette P, Riviello J, Carmant L. ACTH versus vigabatrin therapy in infantile spasms: a retrospective study. Neurology 1999 May; 52(8): 1691–4Google Scholar
  210. 210.
    Kellermann K, Soditt V, Rambeck B, et al. Fatal hepatotoxicity in a child treated with vigabatrin. Acta Neurologica Scandinavica 1996; 93: 380–1PubMedGoogle Scholar
  211. 211.
    Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73(2): 137–50PubMedGoogle Scholar
  212. 212.
    Lyrica [package insert]. New York (NY): Pfizer Inc., 2007Google Scholar
  213. 213.
    Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006; 60: 1497–501PubMedGoogle Scholar
  214. 214.
    Cardot JM, Lecaillon JB, Czendlik C, et al. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm Drug Dispos 1998; 19: 259–62PubMedGoogle Scholar
  215. 215.
    Deeks ED, Scott LJ. Rufinamide. CNS Drugs 2006; 20(9): 751–60PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Harrison School of Pharmacy, Pharmacy PracticeAuburn UniversityAuburnUSA
  2. 2.Department of PediatricsUniversity of South Alabama, School of MedicineMobileUSA
  3. 3.Division of PediatricsUniversity of Alabama at Birmingham, School of MedicineHuntsvilleUSA

Personalised recommendations